NEW YORK – Cancer diagnostics firm PrognomiQ said Tuesday that it has raised $46 million in financing.
The San Mateo, California-based company, which is a spinoff from proteomics tools firm Seer, said it will use the funds to accelerate its multiomic tests for cancer early detection, treatment selection, and patient monitoring.
The round was led by existing investor Bruker with participation from new investors, including Catalio Capital Management, and from previous investors including aMoon, Fidelity Management and Research, funds and accounts advised by T. Rowe Price, Invus, Maverick Ventures, Emerson Collective, and Wing VC.
With the round, PrognomiQ has raised more than $101 million since it launched in September 2020 backed by a $55 million funding round.
"The PrognomiQ team has a unique and novel multiomics approach for early detection of cancer from liquid biopsies," Frank Laukien, president and CEO of Bruker, said in a statement. "If higher sensitivity, earlier cancer detection and cancer precision medicine are to reach their full potential to save or substantially prolong many more patient lives, we need to tap into the rich set of systems biology markers that PrognomiQ can deliver with its unique, next-generation ability to do large-scale, unbiased multiomics studies."